Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Axel A Fauser"'
Autor:
Mohamad Mohty, Myriam Labopin, Reza Tabrizzi, Niklas Theorin, Axel A Fauser, Alessandro Rambaldi, Johan Maertens, Shimon Slavin, Ignazio Majolino, Arnon Nagler, Didier Blaise, Vanderson Rocha
Publikováno v:
Haematologica, Vol 93, Iss 2 (2008)
This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leuke
Externí odkaz:
https://doaj.org/article/e51ba6c1e6b64cbb90fe258ae2ce860f
Autor:
Michael Flasshove, Markus Pfirrmann, Susanne Saußele, Wolf-K. Hofmann, M. P. Kraus, Benjamin Hanfstein, Urs Hess, Rüdiger Hehlmann, R. Mahlberg, Martin C. Müller, Gabriela M. Baerlocher, Tim H. Brümmendorf, Manuel Barreto Miranda, Dominik Heim, Christoph Nerl, Dieter K. Hossfeld, B. Rendenbach, Alice Fabarius, Walter Verbeek, Hans-Jochem Kolb, K. Neben, Stefan W. Krause, Otto Prümmer, Joerg Hasford, Axel A. Fauser, Ulrike Proetel, C. Ploger, Andreas Hochhaus, Michael Lauseker
Publikováno v:
Leukemia
Miranda, M B; Lauseker, M; Kraus, M-P; Proetel, U; Hanfstein, B; Fabarius, A; Baerlocher, Gabriela M.; Heim, D; Hossfeld, D K; Kolb, H-J; Krause, S W; Nerl, C; Brümmendorf, T H; Verbeek, W; Fauser, A A; Prümmer, O; Neben, K; Hess, U; Mahlberg, R; Plöger, C; ... (2016). Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia, 30(6), pp. 1255-1262. Nature Publishing Group 10.1038/leu.2016.20
Leukemia : normal and malignant hemopoiesis 30(6), 1255-1262 (2016). doi:10.1038/leu.2016.20
Miranda, M B; Lauseker, M; Kraus, M-P; Proetel, U; Hanfstein, B; Fabarius, A; Baerlocher, Gabriela M.; Heim, D; Hossfeld, D K; Kolb, H-J; Krause, S W; Nerl, C; Brümmendorf, T H; Verbeek, W; Fauser, A A; Prümmer, O; Neben, K; Hess, U; Mahlberg, R; Plöger, C; ... (2016). Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia, 30(6), pp. 1255-1262. Nature Publishing Group 10.1038/leu.2016.20
Leukemia : normal and malignant hemopoiesis 30(6), 1255-1262 (2016). doi:10.1038/leu.2016.20
Leukemia : normal and malignant hemopoiesis 30(6), 1255-1262 (2016). doi:10.1038/leu.2016.20
Published by Nature Publ. Group, Basingstoke
Published by Nature Publ. Group, Basingstoke
Autor:
S. Frühauf, R. Hansen, H. Munzinger, Urs Hess, X. Schiel, O. Stötzer, Holger Hebart, Mathias Hänel, S. Weidenhöfer, E. Jäger, H. Becker, Susanne Saußele, R. Gaeckler, F. Hartmann, Lorenz Trümper, W. Wuillemin, Thomas Illmer, W. Pommerien, Carlo Aul, P. le Coutre, W. Elsel, Otto Prümmer, A. Wehmeier, O. Klein, F. Schlegel, Sebastien Rinaldetti, D. Kingreen, Martin Bentz, J. Menzel, L. Hahn, R. Pihusch, Michael Schenk, Renate Arnold, Dietrich Kämpfe, B. Oldenkott, Alice Fabarius, M. Hahn, H. Eschenburg, A. Grote-Metke, M. Neise, Y. Dencausse, H. Köster, U. Vehling-Kaiser, M. Wattad, K. Stahlhut, H. Weischer, R. Moeller, Markus Pfirrmann, K. Neben, H. Tessen, A. Raghavachar, Peter Brossart, Hans-Heinrich Wolf, M. Hofknecht, Roland Schroers, Thomas Geer, Matthias Edinger, Axel R. Zander, R. Rudolph, F. Stegelmann, Winfried Gassmann, K. Ranft, A. Matzdorff, Christoph Scheid, M. Sosada, M. Sieber, G. Köchling, W. Fett, T. Herrmann, Rudolf Schlag, C. Maintz, S. Schanz, S. Hentschke, Peter Reichert, Dietrich W. Beelen, Alois Gratwohl, S. Schmitz, Michael Lauseker, Gabriela M. Baerlocher, H. P. Weidelich, F. Müller, B. Sievers, Alexander Kiani, J. Heßling, P. Majunke, W. Hollburg, D. Reschke, S. Wagner, B. Rendenbach, G. Käfer, W. Ludwig, Claudia Haferlach, A. Lochter, G. Baake, A. Schmalenbach, Y. Ko, R. Schwerdtfeger, Cornelius F. Waller, J. Mittermüller, Wolfgang E. Berdel, Walter Verbeek, C. Sperling, T. Fischer Huber, Karsten Spiekermann, C. Spohn, H. Pralle, Ch Scholz, C. Schelenz, H. Schick, A. D. Ho, Robert Dengler, C. Lunscken, D. Assman, H. Hoeffkes, A. Nusch, Hans-Walter Lindemann, B. Göttler, Günter Schlimok, H. Fiechtner, Patrick Wuchter, H. Forstbauer, C. Müller-Naendrup, J. Krauter, M. Planker, W. Langer, L. Schulz, Andreas Hochhaus, Hartmut Link, Philippe Schafhausen, Bernd Hertenstein, Andreas Neubauer, C. Schadeck-Gressel, M. Hoffknecht, L. Balleisen, A. Henzel, E. Ladda, Dieter K. Hossfeld, I. Blau, Jörg Hasford, V. Petersen, Christoph Nerl, M. Flaßhove, C. Lamberti, Stephan Kremers, Wassman, S. Korsten, Hans-Jochem Kolb, G. Adam, Michele Baccarani, M. Demandt, S. Al-Batran, S. Rösel, Jolanta Dengler, T. Neuhaus, Martin Griesshammer, B. Kempf, K. Josten, M. Sauer, W. Gröschel, U. Hieber, V. Runde, A. Urmersbach, Lutz P. Müller, Rüdiger Hehlmann, D. Linck, M. Hemeier, U. Martens, T. Kamp, S. Völkl, C. Diekmann, Andreas Burchert, T. Reiber, S. Bildat, J. Gmür, M. Uppenkamp, M. Simon, T. Zöller, Lothar Kanz, H. Strotkötter, N. Kalhori, R. Janz, Brigitte Schlegelberger, A. Hoyer, Wolfgang Seifarth, S. Stier, Katharina Kohlbrenner, J. Heymanns, J. Schleicher, Stefan W. Krause, M. de Wit, Antonio Pezzutto, D. Behringer, A. Lollert, H. Hitz, J. Janssen, G. Trenn, C. Lange, R. Depenbusch, A. Lindemann, H. Dietzfelbinger, B. Bechtel, B. Koch, B. Uebelmesser, U. Burkhardt, R. Fuchs, M. Schatz, S. Brettner, G. Heil, D. Hossfeld, Norbert Schmitz, C. Scheidegger, D. Reichert, M. Baldus, Michael J. Eckart, Axel A. Fauser, Lida Kalmanti, Birgit Spieß, Jiří Mayer, C. Ploger, C. A. Köhne, C. Priebe-Richter, C. Denzlinger, G. Doering, G. Springer, Tim H. Brümmendorf, Dominik Heim, Michael Kneba, I. M. Pfreundschuh, S. Jacki, M. Stauch, M. Kemmerling, Martin Wernli, A. Bartholomäus, Astghik Voskanyan, B. Sandritter, S. Fetscher, B. Goldmann, M. C. Goebler, C. Falge, Heinz Dürk, L. Fischer von Weikersthal, H. Baurmann, G. Ehninger, E. Schäfer, M. Schröder, F. Möller-Faßbender, K. Tajrobehkar, P. Schmidt, Christian A. Schmidt, A. Waladkhani, W. Freier, F. Henneke
Publikováno v:
Leukemia. 34:2823-2823
Korrektur zu 10.1038/s41375-020-0826-9
Autor:
Michael Pfreundschuh, Matthias Edinger, Martin Wilhelm, Christiane Falge, Jörg Th. Fischer, Bernd Hertenstein, Markus Pfirrmann, Donald Bunjes, J Novotny, Susanne Schnittger, Michael Schatz, Artur Wehmeier, Andreas Hochhaus, Herbert G. Sayer, Ingo G.H. Schmidt-Wolf, Christoph Nerl, Claudia Haferlach, Susanne Saußele, Matthias Fabian, Martin C. Müller, Arnold Ganser, Joerg Hasford, Dieter K. Hossfeld, Anthony D. Ho, Hans-Jochem Kolb, Peter Staib, Herrmann Heimpel, Hartmut Döhner, Axel A. Fauser, Andreas Reiter, Michael Schenk, Renate Arnold, Gabriela M. Baerlocher, Rainer Schwerdtfeger, Carlo Aul, Rüdiger Hehlmann, Rolf Kuse, Thomas Kindler, Axel R. Zander, Gerald Wulf, Norbert Schmitz, Otto Prümmer, Karsten Spiekermann, Maria-Elisabeth Goebeler, Ute Berger, Anne Rosselet, Nicolaus Kröger, Dietrich W. Beelen, Alois Gratwohl, Günter Schlimok, Jiří Mayer, Andrzej Hellmann, Herrad Baurmann, Matthias Bormann, Hans Walter Lindemann, Christof Scheid, E. Schäfer, Guntram Büsche
Publikováno v:
Gratwohl, A; Pfirrmann, M; Zander, A; Kröger, N; Beelen, D; Novotny, J; Nerl, C; Scheid, C; Spiekermann, K; Mayer, J; Sayer, H G; Falge, C; Bunjes, D; Döhner, H; Ganser, A; Schmidt-Wolf, I; Schwerdtfeger, R; Baurmann, H; Kuse, R; Schmitz, N; ... (2016). Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia, 30(3), pp. 562-569. Nature Publishing Group 10.1038/leu.2015.281
Leukemia, vol. 30, no. 3, pp. 562-569
Leukemia
Leukemia, vol. 30, no. 3, pp. 562-569
Leukemia
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343c3126b8797d956f29c42c090048c4
https://doi.org/10.1038/leu.2015.281
https://doi.org/10.1038/leu.2015.281
Autor:
Axel A. Fauser, Eva M. Zopf, Thomas Elter, Klaus Schüle, Eike Nykamp, Ludwig Kraut, Wilhelm Bloch, Freerk T. Baumann
Publikováno v:
European Journal of Haematology. 87:148-156
An allogeneic hematopoietic stem cell transplantation (HSCT) can have profound and lasting adverse effects on a patient’s physical and psychological well-being. So far, only few studies have investigated the effectiveness of physical activity over
Publikováno v:
Bone Marrow Transplantation. 45:355-362
A haematopoietic SCT (HSCT) can cause severe side effects, which may have a profound impact on a patient's life both physically and psychologically. Some studies have shown that physical activity has positive effects for inpatients after an HSCT. The
Autor:
Reza Tabrizzi, Vanderson Rocha, Mohamad Mohty, Didier Blaise, Arnon Nagler, Myriam Labopin, Johan Maertens, Ignazio Majolino, Niklas Theorin, Alessandro Rambaldi, Shimon Slavin, Axel A. Fauser
Publikováno v:
Haematologica. 93:303-306
This retrospective study reported the outcome of 97 adult acute lymphoblastic leukemia patients who received a reduced-intensity conditioning allogeneic stem cell transplantation. With a median follow-up of 2.8 years, two year overall-survival, leuke
Autor:
Lothar Kanz, Olga Marinets, Eckhard Thiel, Ulrich Keilholz, Lutz Uharek, Werner Hopfenmüller, Mathias Freund, H. Einsele, D. W. Beelen, Rudolf Trenschel, Jochen Casper, W. U. Knauf, Martin Schmidt-Hieber, Liisa Volin, Axel A. Fauser, Reinhard Andreesen, T Fietz, Gernot Stuhler, I. W. Blau, Tapani Ruutu
Publikováno v:
Bone Marrow Transplantation. 39:389-396
In recent years, reduced-intensity conditioning (RIC) regimens before allogeneic stem cell transplantation (SCT) are increasingly used in patients not eligible for conventional conditioning. We did a retrospective, multicenter analysis to assess the
Publikováno v:
Deutsche Zeitschrift für Onkologie. 37:152-158
Autor:
Axel A. Fauser, Dietrich W. Beelen, Oliver Basu, Nadezda Basara, Olle Ringdén, Mats Remberger
Publikováno v:
Blood. 105:548-551
The long-term follow-up of a study including 214 patients receiving either peripheral blood stem cells (PBSCs) or bone marrow (BM) from an HLA-A, -B, and -DR–compatible unrelated donor is presented. Median follow-up was 4.4 (2.3-7.3) and 5.0 (0.7-8